Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes

BACKGROUND AND AIMS: To evaluate the effect of mirikizumab, a p19-targeted anti-interleukin-23, on histological and/or endoscopic outcomes in moderately-to-severely active ulcerative colitis [UC]. METHODS: Endoscopic remission [ER], histological improvement [HI], histological remission [HR], histolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Magro, Fernando, Pai, Rish K, Kobayashi, Taku, Jairath, Vipul, Rieder, Florian, Redondo, Isabel, Lissoos, Trevor, Morris, Nathan, Shan, Mingyang, Park, Meekyong, Peyrin-Biroulet, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588772/
https://www.ncbi.nlm.nih.gov/pubmed/37057827
http://dx.doi.org/10.1093/ecco-jcc/jjad050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588772/
https://www.ncbi.nlm.nih.gov/pubmed/37057827
http://dx.doi.org/10.1093/ecco-jcc/jjad050

Ejemplares similares